Surgeons, physiotherapists and details of treatments

Surgeons' training and experience
Surgery was delivered in 23 hospitals by a total of 27 consultants on the UK Genaral Medical Council Specialist Register for Trauma and Orthopaedic Surgery. They had been on the Specialty Register for a mean of 11 years (SD 6.6). The trial surgeons had been performing hip arthroscopy as a consultant for a mean of 9 years (SD 3.6), having received the following dedicated hip preservation training: specialist registrar (n=13), courses (n=24), fellowship (n=14, mean duration 9 months), travelling fellowship (n=8, mean duration 1.6 months). Six surgeons were directors of hip preservation fellowships and 17 were faculty on dedicated hip arthroscopy courses. Trial surgeons reported that they performed a mean of 112 (SD 55) hip arthroscopies a year of which 81 (SD 45) were for FAI syndrome. Each surgeon operated on a mean of 5.3 participants (SD 5.3, median 3, range in the FASHIoN trial.
Surgery delivered
144 patients received their surgery within 12 months of randomisation. Operation notes were available for review in 142 patients.
Reshaping surgery:
• 105 cam only resections,
• 26 cam and pincer resection,
• 8 pincer only resections,
• 3 patients did not have a resection; in two participants their hip was found to be degenerate at surgery and in one instance the operative diagnosis was an isolated labral tear not FAI syndrome.
Labral surgery:
• Debridement; n=57
• Thermal shrinkage n=29
• Anchor repair n=35
• Resection n=5
• Resection of ossified labrum n=2 (as part of a pincer resection)
Chondral surgery:
• Microfracture n=21
• Chondroplasty n=29
• Debridement n=10
Post-operative rehabilitation
There was variatiability in the post-operative rehabilitation protocols between trial centres. Rehabilitation was typically structured in stages over several months and included:
• An immediate post-operative phase to restored hip movement as pain improved
• A phase to restore static stability and movement,
• A phase to restore dynamic stability and movement
• Sports specific training
Physiotherapists' training and experience
Personalised Hip Therapy (PHT) was delivered at 23 hospitals by a total of 47 Chartered Physiotherapists who were registered with the Health and Care Professions Council. In terms of clinical experience, they ranged from NHS Agenda for Change (AfC) band 5 to band 8a (band 5 n=1; band 6 n=11; band 7 n=19; band 8a n=5, band unknown n= 11). AfC is the current NHS grading and pay system, where a band 5 physiotherapist is usually a recently qualified physiotherapist or one with less than three years of experience and a band 8a represents a specialist physiotherapist or an extended scope practitioner.
All PHT physiotherapists treated patients with musculoskeletal conditions within their normal clinical practice. Forty-one (90%) physiotherapists had previously treated patients with FAI syndrome before involvement in the trial. All physiotherapists attended at least one of eight workshops held between 2012 and March 2016.
Physiotherapists delivered a median of 7 PHT sessions each and each physiotherapist treated a median of 2 patients. Typically each site had two trained PHT physiotherapists and they often changed jobs, hence the median number of participants treated by each PHT physiotherapist was lower than that of participants operated upon by each surgeon.
PHT delivered
936 PHT treatment sessions were delivered; 867 (93%) were face to face, 31 (3%) were telephone contacts, 4 (1%) were email contacts, and in 34 (3%) the mode of contact was not recorded. 100 (64%) participants received 6 or more sessions. See Table 1 . Treatment sessions lasted a mean of 30 minutes per session (SD = 11 minutes), with the first assessment and treatment session usually lasting longer.
Number of PHT treatment sessions attended 
Surgical Review Panel process
Vignettes consisting of an anonomysed operation note, two intra operative photographs (usually before and after correction of pathology) and an MRI scan reformatted to show the superior, anterosuperior and anterior head neck junction and acetabular rim, were provided to the surgical review panel. The panel held regular teleconference meetings during the trial to discuss the surgical fidelity. The panel provided an overall rating of either high fidelity or unsatisfactory surgery for each case. This assessment was made subjectively following discussion. When assessing a cam resection the panel assessed the femoral head sphericity and the smoothness of the transition from the head to the femoral neck. When assessing a pincer resection the panel assessed whether the rim remained prominent and whether it was smooth in profile.
Members of PHT Review Panel
All members were part of the group that developed the PHT protocol. 
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PHT Review Panel process
The PHT review panel were presented with case report form for each patient. These detailed the physiotherapy delivered. The panel expected PHT was delivered according to the protocol; particularly that there were between 6 and 10 session, treatment consisted of the 4 core components (a detailed patient assessment, help and advice about FAI syndrome, help with pain relief and an exercise based programme). The panel assessed whether the exercise programme showed evidence of being individualised, supervised and progressive in time.
Details of pre-specified sub group analysis 2 Unit costs were multiplyed by duration of physiotherapy contact (in minutes) and summed across sessions attended to give total treatment cost per patient. Indirect costs associated with delivery of the intervention such as use of the treatment room facility, adminstrative support and over-heads are taken into account in PSSRU unit cost calculations, therefore, separate costs for these were not included in our estimate of PHT costs.
Cost of surgery
A micro-costing exercise was undertaken to estimate resource use and costs associated with delivery of arthrocopic surgery for FAI. Resource use data were collected for a sub-sample of trial participants who had received the surgery using a specially designed costing questionnaire that captured the following items:
• duration of surgery
• post-surgical inpatient length of stay
• number, speciality and grade of clinical staff involved in the surgical procedure
• quantity and type of disposable arthroscopic equipment and/or implants used.
Surgery time was defined from start of anaesthesia to time patient left the operating room on completion of surgery. Inpatient length of stay was counted as one day if the patient was admitted and discharged on the same day, two days if the patient was discharged the next day and so on in line with NHS reference costing methodology. 3 Anaesthetic drugs and associated consumables such as syringes and needles were separately collected during surgery in a small observational study and assumed to be the same for all patients who had the surgery. Operating room/theatre running costs were estimated based on data published by Information Services Scotland. 4 The Scottish data reported total number of theatre hours used and total allocated costs across NHS hospitals in Scotland for the 2015-2016 financial year. Allocated costs are defined to include expendicture on non-clinical staff, property and equipment maintenance, domestics and cleaning, utilities, fittings and capital expenditiure, and excluded clinical staff costs. 5 The hourly running cost of an operating room/ theathre was obtained by dividing the total allocated costs per year by the total theatre time (in hours) per year.
Unit costs of clinical staff time were obtained from the PSSRU Unit Costs of Health and Social Care 2016 compendium. 2 As stated above, these unit costs alrealdy factor in direct cost of staff salaries and employer on-costs and training costs, as well revenue and capital overhaeds, administrative support, office space and work-related travel. The cost of disposal surgical equipment and implants were primarily obtained from the 2016 online edition of the NHS supply chain catalogue. 6 Where cost data were not available from the NHS catalogue, procurement department unit costs from the University Hospital Coventry and Warwickshire were applied. Cost of anaesthetic drugs were obtained from the Prescription Costs Analysis database. 3 Resource use during follow-up Health and socialcare service use data were collected from trial participants for the 3 month period prior to randomisation (to establish baseline data) and the 12 months period post-randomisation. Resource use data were collected at 3 assessment points (baseline, 6 months and 12 months post randomisation) and included:
• details of hospital inpatient and day case admissions
• details of outpatient and accident and emergency attendances
• primary/community care encounters
• use of personal social care services, such as meals on wheels, laundary services, social care contacts, etc.
• prescribed and over the counter medication use
• supplied or self-purchase of walking aids such as crutches, walking sticks and adaptations to home or work environments
• any other additional costs incurred by patients and their families as a result of their hip pain. Examples include private medical costs and out-of-pockect expenditures (e.g. travel costs by patients and family members), childcare costs and lost income.
Resource inputs were valued by attaching unit costs derived from national compendia to resource inputs.
Hospital based services included inpatient admissions, day care and outpatient and accident and emergency attendances, and diagnostic tests and scans. Unit costs for these services were obtained primarily from the 2015/2016 NHS reference costs main schedules. 7 Per diem costs were calculated for each inpatient admission as a weighted average of Healthcare Resource Group (HRG) codes of related procedures and/or clinical conditions. For example, the average cost per day for inpatient stay in an orthopaedic ward with procedures carried out on the hip/leg was calculated as a sum total of the weighted average of lower limb orthopaedics (trauma) HRG codes divided by average length of stay across elective and non-elective inpatient services.
Primary and community health and social care services included face-to-face or telephone contacts and/or home visits by a general practice doctor, practice nurse, community physiotherapy or other community health or social care professionals. Consultation costs were derived from the PSSRU Unit Costs of Health and Social Care 2016 compendium. 2 The cost of private physiotherapy and other private medical costs were obtained from online sources and referenced appropriately in the unit cost tables.
The cost of prescribed medication was obtained primarily from the prescription cost analysis 2016 database and electronic searches of the British National Formulary (BNF) 2016 edition. 3 Typical dosage and duration of treatment reported in the BNF for each medication were used in calculating quantity of individual preparations if the daily dose and/or duration of course of medication were not reported. The quantity of over the counter medicines were rounded to the nearest pack and unit costs obtained from online sources.
The cost of walking aids and adaptations were either provided by the patients themselves (if self-purchased) or taken from the NHS supply chain catalogue if supplied by a health provider during the trial follow-up period. It was assumed that walking aids such as crutches, sticks, grab rail, dressing aids and specially adapted shoes were supplied as part of treatment if the cost of purchase were not provided by trial participants. 6 Patient-level costs were generated for each resource variable by multiplying the quantity reported by the respective unit cost weighted by duration of contact where appopriate. Summary statistics were generated for resource use variables by treatment allocation and assessment point. Between treatment-group differences in resource use and costs at each assessment point were compared using the twosample t-test. Statistical significance was assessed at the 5% significance level. Standard errors are reported for treatment group means and boostrap 95% confidence intervals for the between-group differences in mean resource use and cost estimates.
Measurement of outcomes
The health-related quality of life of trial participants was assessed at baseline and at 6 and 12 months post randomisation using the EuroQol EQ-5D-3L in the feasibility study, the EQ-5D-5L in the main trial, and the SF-12 version 1 in both feasibility and main trial samples. Responses to each health dimension were categorised as optimal or sub-optimal with respect to function where optimal level of function indicates no impairment (for example "no problem" on the EQ-5D-3L dimensions) and sub-optimal indicates any functional impairment. [8] [9] [10] Between-group differences in optimal versus sub-optimal level of function for each health dimension were compared for each outcome measure using chi-squared (χ 2 ) tests.
The responses to each health-related quality of life instrument were converted into health-related quality of life weights (also referred to as utility weights) using established algorithms for each instrument. Utility values were generated using the UK value set for the EQ-5D-3L, the interim cross-walk value set for mapping from the EQ-5D-5L to the EQ-5D-3L, the newly published EQ-5D-5L tariffs for the EQ-5D-5L, and the SF-6D tariff based on SF-12 version 1 responses. [11] [12] [13] [14] Quality-adjusted life-years (QALYs) were generated for each patient using the area under the baseline-adjusted utility curve, assuming linear interpolation between the three utility measurements. QALYs were generated for patients in the feasibility sample using utilities derived from EQ-5D-3L and SF-6D tariffs and for those in the main study sample using the EQ-5D-5L cross-walk tariff, new UK EQ-5D-5L tariff and the SF-6D tariff. [11] [12] [13] [14] Health utility values and QALYs accrued over the 12 month follow-up were summarised by treatment group and assessment point and presented as means and associated standard errors; betweengroup differences were compared using the two-sample t-test, similar to the summary analyses of resource inputs and costs.
Cost-effectiveness analysis methods
Missing data
Multiple imputation by chain equations implemented through the MICE package 15 was used to handle missing costs and health utility data at each assessment point. Multiple imputation avoids problems associated complete case analyses, is consistent with good practice and only requires data to be missing at random. 16 Appropriateness of this missing at random assumption was assessed by comparing the characteristics of patients with and without missing costs and health-related quality of life data at each follow-up time point. Imputations were generated separately by treatment group as recommended by Faria et al. 17 using the predictive mean matching method which has the advantage of preserving non-linear relationships and correlations between variables within the data. Twenty imputed datasets were generated and the analyses fitted to each imputed dataset. The results from the 20 datasets were then combined using Rubin's rules. The imputation, analysis and pooling of results steps were performed simultanously within the MICE package. 15 The imputed data were used to inform the base case and all subgroup and sensitivity analyses with the exception of one sensitivity analysis, which was conducted using only complete data.
Base case cost-effectiveness analysis
The base-case took the form of and intention-to-treat analysis conducted from a UK health and social service perspective. Health outcomes were expressed in QALYs using utilities generated from the EQ-5D-3L (feasibility study participants) and the EQ-5D-5L to EQ-5D-3L crosswalk tariff for the main trial participants. Total costs accrued over 12 months of follow-up were calculated for each patient by summing the delivery costs of the intervention(s) received (irrespective of treatment allocation), and a sum total of follow-up costs reported at the 6 and 12 month assessment points relevant to the perspective of interest.
Two seemingly unrelated normal error regressions were fitted to the data using the Systems fit implementation in R. 18 These were used to simultanouesly estimate incremental costs and benefits of surgery compared with PHT whilst accounting for correlation between the two. The regressions controlled for treatment allocation, sex, recruitment site, type of impingment, baseline costs (regression equation for costs only) and baseline healthrelated quality of life (regression equation for outcomes). The incremental cost-effectiveness ratio (ICER) was calculated by dividing the between-group difference in adjusted mean total costs by the difference in adjusted mean QALYs. The cost-effectiveness of hip arthroscopy was determined by comparing the ICER value to cost-effectiveness thresholds of £20,000 and £30,000 per QALY gaind in line with NICE guidance 19 and to the recent empirical £13,000 per QALY estimate suggested by Claxton et al. 20 The incremental net (monetary) benefit of the surgery compared with PHT was calculated for a range of cost-effectiveness thresholds. Net benefit values reflect the opportunity cost of (or the benefits forgone) from adopting a new treatment when resources could be put to use elsewhere. A positive net benefit would suggests that, on average, the new treatment provides net gain compared with the alternative and can be considered cost-effective at the given cost-effectiveness threshold.
Uncertanty around the mean cost-effectiveness estimates was characterised through a monte carlo method. 21 This involved simulating 1,000 replicates of the ICER from a joint distribution of the incremental costs and QALYs and plotting the simulated ICERs on a cost-effectiveness plane. Cost-effectiveness acceptability curves were also plotted to give graphical display of the probability that surgery is costeffective across a wide range of cost-effectiveness thresholds.
Sensitivity analysis
Sensitivity analyses were conducted to investigate aspects of study design and data collection for which alternative methods exist, but where there is uncertainty regarding which method or approach is best. For example, the cost of surgery was estimated based on data from a sub-sample of patients who had the surgery in the study. Surgery costs can also be obtained through the healthcare resource groups case-mix method. Other sensitivity analyses included broadening the perspective of the analysis to capture wider societal costs and their impact on relative cost-effectiveness of the interventions. A list of all sentivitiy analyses carried out are presented in Table 1 . 
Sub-group analysis
Heterogeneity in cost-effectiveness estimates was explored through the following pre-specified and post-hoc subgroup analyses.
The pre-specified analyses were the following:
• Recruitment period (feasibility versus main trial samples)
• Type of impingement (CAM versus mixed/pincer)
• Age (less than 40 years old versus 40 years or older).
Post-hoc subgroup analyses were the following:
• Sex (female versus male).
• Subgroup of patients in the surgery arm who had surgery within 4 months of randomisaiton.
• Subgroup of patients in the surgery arm who did not undergo surgery within 4 months of randomisation. These last two subgroup analyses were conducted in response to a suggestion at peer-review investigated the impact of the delay to surgery on the within-trial cost-effectiveness results. Patients in the surgery group were categorised based on the median time to surgery of 122 days observed in the trial into (i) those who had surgery within the first 4 months of randomisation (i.e. within 122 days of randomisation) (n=74) and those who did not have surgery within 4 months of randomisaiton (n=75). Each group of patients in the surgery arm was then compared to the whole PHT group (n=177) in a separate subgroup analyses that adjusted for baseline covariates and used imputed costs and QALYs as was done in the base case analysis.
Long-term modelling
The study protocol had also allowed for trial participants to be follow-up beyond the initial 12 month period for up to 3 years and outcome data collected at the end of the second and third year post-randomisation. Given that the 12-month within-trial economic analysis did not show evidence of cost-effectiveness in favour of the surgery, it is doubtful whether long-term economic modelling would be meaningful without this additional data. Also, 14 patients representing 7.3% of the PHT group had crossed-over and recieved the surgery during the 12 months follow-up period. The net effect of patients crossing over to surgery may increase costs in the PHT arm and decrease the incremental costs between surgery and PHT. If more and more PHT patients continue to cross-over to surgery in subsequent years, then they will be picked up at second and third year assessments. Therefore, an assessment of the utility of a long term economic model should be delayed until the second and third year data becomes available. This would provide a more accurate assessment of outcomes over a longer followup period and determine whether modelling is needed to capture the long term (i.e. lifetime) costs and consequences of treatment. Table 2 presents a summary PHT attendance by type of consultation, impingement classification, missed appointments and recruitment site. A total of 1219 physiotherapy appointments were offered to 166 (93.8%) of the 177 patients in the PHT group. Of these, 909 (75%) were face-to-face consultations, 38 (3%) were telephone consultations, 7 (0.6%) were email contacts and 256 (21%) were recorded as unknown or missed appointments. The mean number of physiotherapy contacts among those who attended at least one PHT session was 6 (range 1 to 11) and mean duration across all sessions attended was 178.17 minutes (mean 29min per session). 
Further Health Economics Results
Cost of PHT
Cost of surgery
Estimates of resource use associated with delivery of the surgery and sources of unit cost data for resource inputs are presented Tables 3 to 5 . The mean duration of surgery was 2.12 (range: 1 to 3) hours and the mean length of inpatient stay was 1.6 (range: 1 to 3) days (Table 3 ). The composition of the surgical team/staff remained broadly similar across centres and consisted of 2 surgeons (a consultant and an assistant or registrar), one anaesthetist, a radiographer, up to 2 nurses, 2 operating department practitioners and a healthcare assistant. Unit costs of clinical staff time were obtained from the 2016 edition of the PSSRU Unit Costs of Health and Social care services and ranged from £28 per hour for a healthcare assistant to £137 per hour for consultant surgeon (including qualifications and overheads). The running cost of an operating theatre was estimated based on data published by the Information Services Scotland (ISD). 22, 23 Inpatient stay was assumed to cost £332.77 per day, the excess bed day cost for elective orthopeadics procedures [HN14E: Intermediate Hip Procedures for NonTrauma, 19 years and over, with CC Score 0] in the 2016 reference costs schedules. 24 The unit cost of anaesthetic drugs were obtained from NHS Prescription Cost Analysis 2016 database, 25 electronic searches of the British National Formulary (BNF) 2016 and searches of the literature where necessary. Unit cost of syringes and needles and other medical consumables were obtained from online sources when more direct NHS sources were unavailable.
Across all the 22 centres, the overall mean cost was £3,042 (range of means £2,286 to £40,076), 35.3% of which were staffing costs, 23.5% disposal surgical equipment and implants, 19.4% theatre running costs, 17.8% inpatient costs and 4% represent the cost of anaesthesia including drugs, syringes and needles (Table 4) . 
Guys and St Thomas
(n=1) £657 (-) £1244 (-) £728 (-) £122 (-) £355 (-) £3105 (-)Stanmore (n=1) £734 (-) £1556 (-) £598 (-) £122 (-) £1066 (-) £4076 (-) Oswestry (AJ & RH) (n=1) £1014 (-) £1097 (-) £753 (-) £122 (-) £711 (-) £3697 (-) South Tees (n=2) £925 (380) £1172 (78) £587 (0) £122 (0) £355 (0) £3161 (458) Llandough (Cardiff) (n=4) £563 (98) £970 (77) £564 (32) £122 (0) £355 (0) £2574 (200) Wrexham (n=1) £446 (-) £1446 (-) £846 (-) £122 (-) £711 (-) £3570 (-) North Bristol (n=4) £429 (145) £827 (154) £465 (76) £122 (0) £444 (89) £2286 (448) Spire (n=1) £843 (-) £455 (-) £282 (-) £122 (-) £711 (-) £2412 (-) All centres (n=40) £719 (58) £1067 (47) £591 (23) £122 (0) £542 (31) £3042 (116)
Economic costs
Estimates of the economic costs associated with each intervention are summarised in Table 6 by type of resource and treatment allocation. Among the complete cases, and across the 12-month follow-up period, the mean total cost from a UK health and personal social service perspective were £3,742 in the surgery group and £1531 in the PHT group, generating an unadjusted mean cost-difference of £2,211 and adjusted mean cost-difference of £2,281 (95%CI £1,809, £2,575). Surgery costs accounted for approximately 70% of total unadjusted costs in the surgery group whilst the treatment costs (including surgery costs for PHT patients who had surgery) accounted for only 29% of the total adjusted costs in the PHT group. The corresponding mean total costs estimated from a societal perspective were £5,023. in the surgery group of which 52% is surgery costs, and £1,730 in the PHT group, 26% of which were accounted for by treatment costs, generating an unadjusted cost-difference of £3,354 (95%CI £1,809, £2,757).
Cost-effectiveness results
Base case analysis results Table 7 presents estimates of the cost-effectiveness of hip arthroscopy versus PHT for FAI. In the base case analysis, surgery was associated with adjusted mean additional cost of £2 ,372 (95%CI £938, £3,805) and adjusted mean additional QALYs of -0.018 (95%CI -0.051 to 0.015) per patient compared with PHT over the 12 months of followup. On average, surgery was more expensive and marginally less effective than PHT in the adjusted analysis during the first year of follow-up. The mean base case incremental cost-effectiveness ratio (ICER) thus suggest that surgery was dominated by PHT at 12 months post-randomisation. Figure 1 shows the uncertainty around this central estimate of the ICER. The graph on the left-hand-side of the figure displays 1,000 simulated replicates of the ICER on a costeffectiveness plane whilst the right graph display the probability that surgery is cost-effective compared with PHT for a range of cost-effectiveness thresholds. Almost all simulated replicates of the ICER fell to the left-hand side of the £30,000 and £50,000 per QALY cost-effectiveness threshold lines with the central estimate (indicated by the black diamond) falling in the north-west quadrant. This suggests that surgery is unlikely to be cost-effective at the £20,000 to £30,000 per QALY threshold range (right plot), which NICE currently uses to determine the cost-effectiveness of health technologies. 26 The graph on the right-hand-side of the plot show that probability that surgery is cost-effective compared with PHT is close to zero for threshold values less than £100,0000 per QALY.
Sensitivity analysis results
Of the sensitivity analyses performed, only the unadjusted analysis generated a difference in mean QALYs of 0.001 in favour of the surgery ( Table 7 ). The probability that surgery is cost-effective was 0.005 at £30,000 per QALY and no more than 0.08 at £50,000 per QALY. All other sensitivity analyses adjusted for baseline characteristics such as sex, impingement type, study site, healthcare service use prior to randomisation and health-related quality of life. In the adjusted sensitivity analyses, surgery was significantly more expensive (adjusted mean difference in costs ranged from £2,186 to £6,389) and generated fewer QALYs (adjusted mean difference in QALYs ranged from -0.028 to -0.002) on average than PHT over 12 months of follow-up.
Subgroup analysis results
The subgroup analyses revealed substantial uncertainty around the central estimates of incremental costs and incremental QALYs because of the reduced sample size in each subgroup but the direction of relative cost-effectiveness of the interventions remained mostly the same as in the base-case analysis (see Table 7 ). Surgery generated fewer QALYs on average (adjusted mean difference in QALYs ranged from -0.002 to -0.029) and was significantly more expensive (adjusted mean difference in costs ranged from £1,863 to £3,442) than PHT. The only exception is the subgroup of patients in the surgery arm who had surgery within first 4 months after randomisation (n=74). In this post-hoc analysis conducted in response to a suggestion at peer-review, surgery generated mean incremental costs of £4,323 and adjusted mean incremental QALYs of 0.004 compared with PHT with an ICER of £1,080,750 per QALY gained at 12 months from randomisation. 2. Per protocol sample 1: Restricted analysis to patients who received the allocated treatment-arm intervention (i.e. excluded cross-overs, surgery patients who did not have surgery and patients in the PHT arms who did not have PHT).
3. Per protocol sample 2 -Restricted analysis to patients whose surgery or PHT was deemed to be of good quality as assessed by clinical panel. Cost−effectiveness threshold Probability that surgery is cost−effective
